AI Article Synopsis
- The study aimed to evaluate the economic impact of etanercept treatment on health resource usage among French rheumatoid arthritis (RA) patients.
- After starting etanercept, the yearly cost per patient rose significantly, showing a shift in medical expense distribution towards pharmaceuticals.
- Although there were minor reductions in NSAIDs and physiotherapy costs, overall health resource consumption did not decrease, indicating the need for more long-term research to assess potential economic benefits.
Article Abstract
Introduction: Economical impact of rheumatoid arthritis (RA) has been widely modified thanks to TNF inhibitors. Our study aims to estimate the impact etanercept prescription, in term of health resources consumption, within a regional cohort of French RA patients.
Methods: The study included 148 RA patients, with a mean follow-up duration of 343 days before and after etanercept initiation. Data were anonymously collected from ERASME database of French Health Insurance in Midi-Pyrénées region. A patient-by-patient microcosting approach was performed.
Results: The average annual cost per patient, attributable to RA, was 2.8 times higher after treatment by etanercept than before (15,148.57euro versus 5248.95euro). We observed a rise in pharmaceutical costs, from 11.7% of direct medical costs before to 69.7% after etanercept initiation (120.12euro versus 9995.23euro). We observed a small decrease particularly for NSAIDs (142.14euro versus 102.21euro) and physiotherapy (286.40euro versus 138.77euro). Attributable act costs and indirect costs did not differ before and after etanercept initiation.
Discussion: In this short-term study, initiation of etanercept in RA patients did not come along with a decrease of consumption of health resources. Long-term studies are needed to reveal a potential economical advantage as a consequence of the clinical, structural and functional efficacy of anti-TNF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbspin.2007.04.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities.
Expert Opin Biol Ther
January 2025
Department of Pediatric Rheumatology, Kocaeli University, Kocaeli, Turkey.
Article Synopsis
- Biosimilars are biologic drugs that mimic established medications for treating rheumatic diseases and become available as cost-effective alternatives once original patents expire.
- Since their introduction in pediatric rheumatology in 2013, several biosimilars have been launched, offering more treatment options for children with conditions like juvenile idiopathic arthritis.
- The article emphasizes the need for education and effective communication among healthcare providers and patients to enhance understanding and ensure proper use of biosimilars.
Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis.
BMJ Med
October 2024
MAGIC Evidence Ecosystem Foundation, Oslo, Norway.
Objective: To address the efficacy and safety of proactive therapeutic drug monitoring of biologic drugs for patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis.
Design: Systematic review and meta-analysis.
Data Sources: Medline, Embase, Central, and CINAHL, from database inception to 23 May 2024.
The role of neutrophils in pain: systematic review and meta-analysis of animal studies.
Pain
October 2024
Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain.
The peripheral inflammatory response is an attractive therapeutic target for pain treatment. Neutrophils are the first circulating inflammatory cells recruited to sites of injury, but their contribution to pain outcomes is unclear. We performed a systematic review and meta-analysis of original preclinical studies, which evaluated the effect of preemptive neutrophil depletion on pain outcomes (PROSPERO registration number: CRD42022364004).
View Article and Find Full Text PDFPerspectives on the clinical use of anti-amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology.
Alzheimers Dement (N Y)
September 2024
Departments of Internal Medicine, Neurology and Pathology University of Kentucky College of Medicine Lexington Kentucky USA.
Article Synopsis
- The introduction discusses the concerns surrounding the use of disease-modifying therapies for Alzheimer's disease, such as their clinical benefits, risks, costs, and the hesitation of clinicians to prescribe them.
- The study compares lecanemab, an anti-amyloid therapy for Alzheimer's, with four other biologic agents used in various diseases, focusing on their costs, benefits, and risks.
- Results indicate that the costs, clinical benefits, and safety of anti-amyloid therapies are similar to those of the other biologics, suggesting a promising future for Alzheimer's treatments.
Systemic low-dose anti-fibrotic treatment attenuates ovarian aging in the mouse.
Geroscience
September 2024
Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
The female reproductive system is one of the first to age in humans, resulting in infertility and endocrine disruptions. The aging ovary assumes a fibro-inflammatory milieu which negatively impacts gamete quantity and quality as well as ovulation. Here, we tested whether the systemic delivery of anti-inflammatory (Etanercept) or anti-fibrotic (Pirfenidone) drugs attenuates ovarian aging in mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!